Cargando…

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. This study was composed of a dose-escalation part with AUY922 administered weekly at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Anthony, Rea, Daniel, Ahmed, Samreen, Beck, J. Thaddeus, López, Rafael López, Biganzoli, Laura, Armstrong, Anne C., Aglietta, Massimo, Alba, Emilio, Campone, Mario, Schmitz, Shu-Fang Hsu, Lefebvre, Caroline, Akimov, Mikhail, Lee, Soo-Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122341/ https://www.ncbi.nlm.nih.gov/pubmed/27129177 http://dx.doi.org/10.18632/oncotarget.8974

Ejemplares similares

Complex Crystal Structure Determination of Hsp90(N)-NVP-AUY922 and In Vitro Anti-NSCLC Activity of NVP-AUY922
por: He, Chun-Xia, et al.
Publicado: (2022)

Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
por: CHENG, WEI, et al.
Publicado: (2015)

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
por: ZITZMANN, KATHRIN, et al.
Publicado: (2013)

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
por: Park, Kang-Seo, et al.
Publicado: (2018)

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
por: Lian, Jianpo, et al.
Publicado: (2017)

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
por: Wang, Chun Yan, et al.
Publicado: (2016)

HSP90 Inhibitor, NVP-AUY922, Improves Myelination in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic Mice
por: Chittoor-Vinod, Vinita G., et al.
Publicado: (2019)

HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells
por: Bai, Jingchao, et al.
Publicado: (2017)

The HSP90 Inhibitor, AUY-922, Ameliorates the Development of Nitrogen Mustard-Induced Pulmonary Fibrosis and Lung Dysfunction in Mice
por: Solopov, Pavel, et al.
Publicado: (2020)

Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922
por: Kühnel, Annett, et al.
Publicado: (2019)

The Co-Chaperone Hch1 Regulates Hsp90 Function Differently than Its Homologue Aha1 and Confers Sensitivity to Yeast to the Hsp90 Inhibitor NVP-AUY922
por: Armstrong, Heather, et al.
Publicado: (2012)

HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells
por: Tao, Wenjing, et al.
Publicado: (2015)

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
por: Jensen, Michael Rugaard, et al.
Publicado: (2008)

The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage
por: Zaidi, Shane, et al.
Publicado: (2012)

Preferential radiosensitization to glioblastoma cancer stem cell-like cells by a Hsp90 inhibitor, N-vinylpyrrolidone-AUY922
por: Tani, Toshiaki, et al.
Publicado: (2022)

Hsp90 Inhibitor; NVP-AUY922 in Combination with Doxorubicin Induces Apoptosis and Downregulates VEGF in MCF-7 Breast Cancer Cell Line
por: Mohammadian, Mahshid, et al.
Publicado: (2020)

Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma
por: ISHIKAWA, CHIE, et al.
Publicado: (2016)

MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule
por: Grabenbauer, Felix, et al.
Publicado: (2018)

The HSP90 Inhibitor, AUY-922, Protects and Repairs Human Lung Microvascular Endothelial Cells from Hydrochloric Acid-Induced Endothelial Barrier Dysfunction
por: Colunga Biancatelli, Ruben M. L., et al.
Publicado: (2021)

The Role of HSP70 in the Protective Effects of NVP-AUY922 on Multiple Organ Dysfunction Syndrome in Endotoxemic Rats
por: Liu, Pang-Yen, et al.
Publicado: (2021)

AUY922 induces retinal toxicity through attenuating TRPM1
por: Shen, Che-Hung, et al.
Publicado: (2021)

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012)

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
por: Chandarlapaty, Sarat, et al.
Publicado: (2009)

A Low Membrane Hsp70 Expression in Tumor Cells With Impaired Lactate Metabolism Mediates Radiosensitization by NVP-AUY922
por: Schwab, Melissa, et al.
Publicado: (2022)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia–lymphoma cells
por: Taniguchi, Hiroaki, et al.
Publicado: (2014)

Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?()
por: Mayor-López, Leticia, et al.
Publicado: (2014)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
por: Park, Jung Min, et al.
Publicado: (2020)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

NVP-AUY922 alleviates radiation-induced lung injury via inhibition of autophagy-dependent ferroptosis
por: Li, Li, et al.
Publicado: (2022)

Elucidation of the Molecular Pathways Involved in the Protective Effects of AUY-922 in LPS-Induced Inflammation in Mouse Lungs
por: Akhter, Mohammad S., et al.
Publicado: (2021)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

Heat shock protein 90 inhibitor AUY922 attenuates platelet-derived growth factor-BB-induced migration and proliferation of vascular smooth muscle cells
por: Kim, Jisu, et al.
Publicado: (2020)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
por: Levicki, Rea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7k1uahg256jec3u5du8gfi91p5